

56 **Abstract**

57 **Background:** During the COVID-19 pandemic, trials on convalescent plasma (ConvP) were 58 performed without preceding dose-finding studies. This study aimed to assess potential protective 59 dosing regimens by constructing a population pharmacokinetic (popPK) model describing neutralizing 60 antibody (Nab) titers following the administration of ConvP or hyperimmune globulins(COVIg).

61 **Methods:** Immunocompromised patients, testing negative for anti-SARS-CoV-2 spike antibodies 62 despite vaccination received a range of anti-SARS-CoV-2 antibodies in the form of COVIg or ConvP

63 infusion. The popPK analysis was performed using NONMEM v7.4. Monte Carlo simulations were

64 performed to assess potential COVIg and ConvP dosing regimens for prevention of COVID-19.

65 **Results:** 44 patients were enrolled, and data from 42 were used for constructing the popPK model. A 66 two-compartment elimination model with mixed residual error best described the Nab-titers after 67 administration. Inter individual variation was associated to CL (44.3%), V1 (27.3%), and V2 (29.2%). 68 Lean body weight and type of treatment (ConvP/COVIg) were associated with V1 and V2, 69 respectively. Median elimination half-life was 20 days (interquartile-range: 17–25 days). Simulations 70 demonstrated that even monthly infusions of 600ml of the ConvP or COVIg used in this trial would not 71 achieve potentially protective serum antibody levels for >90% of the time. However, as a result of 72 hybrid immunity and/or repeated vaccination plasma donors with extremely high Nab-titers are now 73 readily available, and a >90% target attainment should be possible.

74 **Conclusion:** The results of this study may inform future intervention studies on the prophylactic and 75 therapeutic use of antiviral antibodies in the form of ConvP or COVIg.

77 **Introduction**

78 Since the start of the pandemic, COVID-19 has taken millions of lives.(1) Effective vaccines can now 79 prevent severe COVID-19 disease, hospitalization and mortality.(2-4) Unfortunately, a heterogeneous 80 group of patients (e.g. those with solid organ transplant, hematological malignancies, or with anti-81 CD20 therapy) still have a poor or completely absent humoral immune response after primary 82 vaccination as well as boosters.(5) They continue to be at risk for a prolonged and/or severe COVID-83 19 disease.(6)

84 By mid-2021, several monoclonal virus neutralizing antibodies (mAbs) had become available as a 85 treatment in parts of the world and can also be used as pre- or post-exposure prophylaxis.(7, 8) MAbs 86 target one specific epitope in the spike protein. Unfortunately, subsequent SARS-CoV-2 variants 87 accumulated mutations in these epitopes which resulted in loss of activity against these variants.(9, 88 10)

89 In contrast to mAbs, polyclonal antibodies (pAbs) may be less susceptible to changes in the spike 90 protein.(11, 12) Both convalescent plasma (ConvP) and hyperimmune globulins (COVIg) are forms of 91 pAbs. ConvP is plasma from donors who have recovered from or were vaccinated against SARS-92 CoV-2.(13) COVIg is an intravenous immunoglobulin product produced from pooled plasma from 93 more than 1000 donors and included ConvP donations.(14) The main advantage of ConvP is that it 94 can be collected very early on in a pandemic, but its antiviral activity varies between each donor. In 95 contrast, it takes several months to produce a first batch of COVIg, but it is more polyclonal than 96 ConvP, the antibody content is constant in each vial of a batch, and ABO blood group matching is not 97 required.

98 An unprecedented number of trials on the efficacy of ConvP and a few as well on COVIg as a 99 treatment for COVID-19 were completed during the first 24 months into the pandemic.(15, 16) The 100 results of these trials have been contradictory. As with mAbs, most evidence in favor of ConvP has 101 been generated in patients very early after symptom onset and in the context of 102 immunodeficiency.(17, 18) More importantly, several animal studies and a recent meta-analysis on 103 outpatient ConvP therapy showed that a high enough SARS-CoV-2 spike antibody titer is essential to 104 observe a therapeutic benefit.(16, 19, 20) MAbs as well as pAbs may also be used to prevent SARS-105 CoV-2-virus infections in immunocompromised patients who lack an endogenous antibody response

- 106 after vaccination. However, dosing regimens of ConvP or COVIg that result in a potentially protective
- 107 neutralizing antibody (Nab) titer for a minimum duration of e.g. 28 days are unknown because proper
- 108 dose-finding studies with ConvP and COVIg remain unavailable.
- 109 This study aimed to establish a population pharmacokinetic (PK) model that is able to predict Nab-
- 110 titers obtained after infusion of SARS-CoV-2 antibodies using ConvP or COVIg and can be applied to
- 111 assess potential protective dosing regimens.

113 **Methods**

114 *Study design*

115 A single-center, open label, phase I/II prospective non-randomized trial (Trial NL9379) was conducted 116 at the Erasmus Medical Center (Rotterdam, the Netherlands). The protocol was approved by the 117 Dutch competent authority (CCMO) and the institutional review board (METC) at Erasmus MC. 118 Written informed consent was obtained from all patients.

119 Based on the availability of ConvP and later of COVIg, the inclusion of a total of 104 patients was 120 planned across groups of different doses and products. In figure S1, the study design is presented in 121 detail. Treatment allocation (ConvP/COVIg) was open-label. These study arms were further divided 122 into different volumes and concentrations. The batches with high Nab-titers were tested first. Patients 123 in the ConvP group were allocated to a predefined volume and Nab-titer based on ABO compatibility. 124 Patients included in the COVIg arm could participate a second time in a ConvP arm of the study at the 125 time they had become SARS-CoV-2 spike antibody negative.

126

127 *Study products*

128 ConvP was provided by the Dutch bloodbank (Sanquin Blood Supply). Donors met the standard 129 plasma donor criteria, had a history of symptomatic COVID-19, and had recovered for at least 14 130 days. COVIg was manufactured by Prothya Biosolutions and provided by the Dutch Ministry of Health, 131 Welfare and Sport. These particular batches were derived from pooled plasma from at least 1000 132 donors, including ConvP donations. Both products were produced while the ancestral variant (Wuhan-133 1) type was dominant in the Netherlands and, therefore, the Nab-titer against this strain was 134 measured. The methods of the Nab-titer measurement are described in the supplementary methods 135 (S2). Antibody treatment was administered intravenously. Since ConvP was collected before anti-136 SARS-CoV-2 vaccines had become available, plasma with very high Nab-titers was rare and the 137 majority of the ConvP from these non-vaccinated donors had a Nab-titer ranging between 270 and 138 $\,$ 500 IUmL⁻¹. In this study, ConvP with a Nab-titer of 500 and 910 IUmL⁻¹ was used and is referred to 139 as intermediate-titer and high-titer ConvP, respectively. By pooling regular plasma with ConvP, 140 Prothya was able to produce two batches of COVIg with an increased Nab-titer of 270 and 910 IUmL 141 $\frac{1}{1}$ These products will be referred to as low-titer and high-titer COVIg, respectively. The Nab-titer,

142 given in IUmL⁻¹, is a unit of antibody neutralization of the ancestral SARS-COV-2 variant, as described 143 by Nguyen et al. It facilitates the comparison of Nab-titers between a broad range of in-house virus 144 neutralization tests.(21)

145 Because IgG titers correlated well with neutralization assays of the ancestral virus, titers of IgG 146 antibodies against the spike protein measured with the LIAISON® SARS-CoV-2 TrimericS IgG assay 147 (DiaSorin) were used.(21). The LIAISON[®] SARS-CoV-2 TrimericS IgG assay comprised a 148 chemiluminescence immunoassay (CLIA) determining the anti-trimeric spike protein-specific IgG 149 antibodies. Results of the CLIA are reported in binding affinity units/mL (BAUmL⁻¹), which is the 150 preferred unit for binding capacity by the WHO.(22-24) CLIA was performed on 11 of the 13 151 administered ConvP units from which median binding capacities were 3230 BAUmL $^{-1}$ and 3070 152 BAUmL⁻¹ for the intermediate and high Nab-titer, respectively. CLIA was performed ten times on the 153 high Nab-titer COVIg batch (910 IUmL⁻¹), from which a median of 3985 BAUmL⁻¹ was obtained. For a 154 rough estimate of the Nab-titer in $IUML^{-1}$, the result of the LIAISON® SARS-CoV-2 TrimericS IgG 155 assay can be divided by 4.

156

157 *Patient selection*

158 Patients were at least 18 years old and did not have anti-SARS-CoV-2 antibodies at baseline. First, 159 patients who had received B-cell depleting therapy were included but after the start of the vaccination 160 campaign, all patients lacking anti-SARS-CoV-2 antibodies at least two weeks after full vaccination 161 (two mRNA vaccines, two adenovirus vector vaccines (ChAdOx1-S), or one adenovirus vector 162 vaccine (Ad26.COV2.S)) could participate in the study as well. Patients were screened with a point-of-163 care antibody test (Roche SARS-CoV-2 Rapid Antibody Test[®]). Negative test results were verified by 164 the DiaSorin CLIA test and were deemed negative if Nab-titers were <33.8 BAUmL⁻¹ according to the 165 manufacturer's instructions.(23) Patients had no symptoms of SARS-CoV-2 infection and tested 166 negative with a qPCR test at the time of screening for the study.

168 *Clinical and biochemical monitoring*

- 169 SARS-CoV-2 spike antibody measurement was performed using CLIA at baseline and, subsequently,
- 170 after 24 and 48 hours and after 1, 2, 4, 6, 8, 12, 18, and 24 weeks or until the Nab-titer had become
- 171 negative $(\leq 33.8 \text{ BAUmL}^{-1})$ again. Blood sampling was also halted if the patient received another anti-
- 172 SARS-CoV-2 vaccination during follow-up or had a breakthrough infection.

173

174 *Primary endpoints*

175 *Population pharmacokinetic analysis*

176 To perform a population PK analysis, the measured Nab-titers versus time curves from ConvP and 177 COVIg were described using non-linear mixed-effect modeling with NONMEM v7.4 (ICON 178 Development Solutions, Ellicott City, MD, USA), which was guided using PsN v4.9.0. Pirana v2.9.9 179 was used for model management and R v4.2.1 (R Core Team, 2020) with Xpose v4.5.3 were used for 180 graphical model diagnostics.(25-27) For obtaining the model parameters, first-order conditional 181 estimation (FOCE) was applied with epsilon-eta interaction.

182

183 *Model development*

184 Model development commenced with evaluating the most parsimonious compartment model to 185 describe the Nab-titer versus time data with initial parameter values obtained from the literature.(28, 186 29) For constructing the statistical model, the residual unexplained variability (RUV) was evaluated 187 using an additional, proportional, or mixed (additive and proportional) error model. Moreover, inter-188 individual variability (IIV) was evaluated for each parameter separately using a log-normal distribution. 189 Inter-occasion variability (IOV) was not estimated, as only data from one dosing event was collected. 190 Model building was conducted using a stepwise approach, as the addition of parameters to the model 191 was evaluated one by one.

192

193 *Covariate analysis*

194 In the covariate analysis, the patient and treatment characteristics were used to explain the obtained 195 IIV for the model PK parameters. Selection of the covariate relationships was based on biological and

196 clinical plausibility. For evaluating the dichotomous covariate relationships, the following model was 197 applied:

$$
\theta_{TV,i} = \theta_{pop} * \theta_{COV}^{COV}
$$

198 in which $\theta_{TV,i}$ is the typical value for the individual patient *i*, θ_{pop} is the population PK parameter value, 199 *θcov* the parameter describing the covariate effect and *COV* is the covariate value being 1 if present 200 and 0 otherwise. For the continuous covariate relationships, the following relationships (linear, power, 201 and exponential) were applied:

$$
\theta_{TV} = \theta_{Pop} * (1 + \theta_{Cov} * (COV - COV_{med}))
$$

$$
\theta_{TV} = \theta_{Pop} * \left(\frac{COV}{COV_{med}}\right)^{\theta_{Cov}}
$$

$$
\theta_{TV} = \theta_{Pop} * e^{(\theta_{Cov} * (COV - COV_{med}))}
$$

202 in which *COVmed* is the median for the covariate value. Before applying a covariate model, the 203 plausibility of that relationship was first evaluated using graphical exploration. The covariate model 204 was constructed using a standard forward inclusion (*p*=0.05, df=1) and backward elimination (*p*=0.01, 205 df=1) procedure.

206

207 *Model evaluation*

208 The ability of the model to predict the Nab-titer measurements was described using an objective 209 function value (OFV). As the OFV is χ_2 distributed, the difference between the OFVs (dOFV) from two 210 hierarchical models was used for model selection and dOFV values of 3.84 and 6.64 indicated a 211 significant difference of *p*<0.05 and *p*<0.01 for one degree of freedom, respectively.

212 Model evaluation and selection were also based on graphical exploration using goodness-of-fit (GOF) 213 plots, and prediction-corrected visual predictive checks (pcVPCs). Furthermore, the robustness of the 214 parameter estimation from the final model was evaluated by non-parametric bootstrap analysis with 215 2000 replications.

217 *Dosing regimen simulation*

- 218 To verify which dosing regimen would result in predefined Nab-titer targets, Monte Carlo simulations 219 of different dosing regimens were conducted using the final model. For the covariate relationships of 220 the final model, values were taken randomly from the study cohort. Dosing regimens were rounded to 221 the nearest practical volume. 222 223 *Secondary endpoints* 224 To evaluate the protective effect of ConvP and COVIg, patients were instructed to undergo PCR 225 testing when they would become symptomatic in order to detect potential breakthrough SARS-CoV-2
- 226 infections. If possible, the viral strain was sequenced for patients admitted to the hospital. For
- 227 investigating the safety of ConvP and COVIg, serious adverse events (SAE) were assessed.

229 **Results**

230 *Patient population and follow-up*

231 Patients were screened for eligibility between April 2021 and April 2022. The study was terminated 232 prematurely due to the emergence of the Omicron variant (B.1.1.529) which became the dominant 233 variant in early 2022 in the Netherlands.(30) Indeed, as the ConvP and COVIg available for the study 234 had a much lower Nab-titer against this B1.1.529 variant, we did not expect any further potential 235 benefit from study participation for the individual patient.

236 In total, 60 patients were screened and 44 were enrolled in the study (Figure 1). Patients were 237 allocated to the intermediate and high Nab-titer groups first. One patient in the COVIg group was 238 excluded from further analysis since the confirmatory anti-SARS-CoV-2 antibody test turned out 239 positive at baseline before dose administration. In addition, one patient from the ConvP group was 240 excluded since this patient accidently received plasma without SARS-CoV-2 neutralizing antibodies. 241 Demographics and baseline characteristics were similar for both treatment groups (Table 1 and Table 242 S3).

243 In total, 86% of the patients (36/42) could be followed until SARS-COV-2 spike antibodies had 244 become negative again. Antibody measurement was halted in three patients because of a 245 breakthrough infection, and in one patient due to an antibody response after an additional booster 246 vaccination during follow-up. In one patient, antibodies remained present after 24 weeks. However, 247 the concentration of antibodies on this last study visit was nearly negative (35.8 BAUmL⁻¹).

248

249 *Population PK analysis*

250 Data from 42 patients were used for constructing of the population PK model. The Nab-titers obtained 251 after dose administration were most adequately described using a two-compartment model with a 252 mixed residual error model and IIV associated with CL, V1, and V2 (Table 2). The latter model was, 253 subsequently, used for the covariate analysis. In the covariate analysis, lean body weight allowed to 254 explain 6.5% of the estimated IIV for V1 using a power relationship most adequately. Moreover, a 255 dichotomous covariate relationship distinguishing between the administration of ConvP or COVIg 256 allowed explaining 15.3% of the IIV estimated for V2. Using the latter covariate relationship, the value

257 for V2 was increased by a factor of 1.99 when ConvP was administered. This reduced the population 258 PK parameter value of the base model estimated for V2 from 2700 mL to 1640 mL.

259 In the group receiving high Nab-titer COVIg, anti-SARS-CoV-2 antibodies were measurable for a 260 median duration of 41 (27 – 56) and 56 (52 – 84) days after 150 or 300 mL, respectively. Antibodies 261 remained detectable for a longer time in patients who received ConvP than those who received 262 COVIg independent of the administered volume and Nab-titer (Table 2). However, the median 263 elimination half-life of ConvP and COVIg was comparable with 18.6 days and 20.3 days, respectively 264 (Table S4). As expected, the peak Nab-titer was highest in the group that received 600mL ConvP with 265 a Nab-titer of 500 IUmL $^{-1}$. Duration of seropositivity for anti-SARS-CoV-2 antibodies and peak 266 antibody concentration are presented in Table 2.

267

268 *Model evaluation*

269 In Figure 2, the goodness-of-fit (GOF) plots for the final model are shown in which the adequacy of 270 the model predictions is demonstrated. Both the individual and population predictions of the 271 neutralizing antibody levels were symmetrically distributed around the line of identity ($y=x$), showing 272 that accurate predictions of the Nab-titers from ConvP and COVIg were obtained using the final 273 model. Moreover, the prediction-corrected visual predictive check (pcVPC) (Figure 3A) showed the 274 accuracy of the final model as all quantiles from the measured Nab-titers (solid lines) were within their 275 respective prediction intervals (shaded areas). However, when presented on the logarithmic scale the 276 latest measured Nab-titers were slightly above the simulated Nab-titers (Figure 3B). The latter was 277 due to the lowest amount of measured Nab-titers being present for that time period.

278 The bootstrap analysis showed that the model parameters were adequately estimated, as all median 279 parameter estimates from the bootstrap were similar to that of the final model.

280

281 *Dosing regimens simulations*

282 Figure 4 depicts the Monte Carlo simulations evaluating the optimal dosing regimen of ConvP and 283 COVIg. When dosing with 600mL of ConvP every 56 days (8 weeks), none of the simulated plasma 284 Nab-titers achieved the 90% probability target attainment (PTA) for the 300 BAUmL⁻¹ threshold. 285 However, reducing the dosing interval to 28 days and using ConvP with a Nab-titer of at least 12,000

289

290 *Secondary endpoint*

291 *Breakthrough infections*

292 Three patients had a breakthrough COVID-19 infection at a time when infused anti-spike antibodies 293 were detectable. Two of them had received ConvP and one COVIg (Table 3). These breakthrough 294 infections occurred with the most recently measured Nab-titer preceding the infection being 74.5 295 BAUmL⁻¹, 51.2 BAUmL⁻¹ and 68.6 BAUmL⁻¹. These antibody titers were measured 31, 27, and two 296 days before the first day of symptoms respectively. One of these patients required hospitalization. 297 This patient was previously treated with anti-CD20 agents and was infected with the Delta (AY.9.2) 298 variant. Treatment with casirivimab/imdevimab and dexamethasone was applied due to hypoxemia 299 requiring supplemental oxygen. After five days, the patient was discharged. The two other patients 300 were infected in the first trimester of 2022 at the time when Omicron BA.1 and BA.2 were the 301 dominant strains in the Netherlands. These patients made a full recovery without hospital admission.

302

303 *Serious adverse events*

304 The administration of ConvP and COVIg was deemed safe. A SAE was reported in two patients 305 (Table 3). However, these SAEs were unrelated to the studied products and were reported as an 306 episode of hospitalization. The first patient was hospitalized due to COVID-19, and the second patient 307 was due to a community-acquired pneumonia. Both patients recovered completely.

309 **Discussion**

310 In this study, a population PK model predicting the Nab-titers after ConvP and COVIg administration 311 was constructed. The adequacy of the model predictions was demonstrated using GOF plots and a 312 pcVPC. Furthermore, a bootstrap analysis showed the robustness of the parameter estimates from 313 the final model. Lean body weight was associated with V1. Concerning V2, its value increased 314 approximately two times with administration of ConvP as compared with COVIg. Finally, Monte Carlo 315 simulations showed that monthly dosing of ConvP with very high-titer ConvP (12,000 BAUmL⁻¹) could 316 attain the 90% PTA for the 300 BAUmL⁻¹ target. To our knowledge, this is the first population PK 317 model predicting Nab-titer after the administration of ConvP or COVIg.

318 In general, the elimination half-life of intravenous immunoglobulins ranges from 7 to 21 days. 319 However, less is known about the elimination half-life of IgG subgroups targeting a specific antigen 320 such as the spike protein of SARS-CoV-2.(28, 31) Before this trial, only a few studies have been 321 performed evaluating the pharmacokinetic and pharmacodynamic characteristics of these pAbs. In a 322 hamster model very high-titer COVIg (pseudovirus virus neutralization 50% titer: 1/1240) had a 323 median elimination half-life of 124 hours.(32) In children, Gordon et al. investigated the PK of high-324 titer ConvP (Nab-titer of 1/320 anti-spike IgG, Euro-Immun) and found an elimination half-life for anti-325 SARS-CoV-2 IgG of 15 days whereas the median elimination half-life of pAbs in our population 326 ranged between 18.6 and 20.6 days.(29)

327 A two-compartment model described the measured Nab-titers most adequately. In contrast to our 328 model, Gordon et al. did not find body weight associated with clearance of the antibodies.(29) During 329 the first elimination phase, a rapid decline in Nab-titers was observed in the first days after dose 330 administration. During the distribution phase, IgG leaves the blood vasculature into lymph and 331 extracellular compartments and slowly diffuses back into the blood circulation.(28) This rapid decline 332 in Nab-titer may pose a problem for attaining higher Nab-titers for a long period and, thus, 333 compromising the use in a prophylactic setting.(33) Adjustment of the Fc-receptor in antibodies is a 334 strategy performed in mAbs and can prolong the elimination half-life of these antibodies.(31) 335 Unfortunately, this is not possible in donor-based pAbs. Aside from this rapid decline, dose dilution in 336 the systemic circulation is another factor that brings the need for very high-titer therapy.(33) In this 337 study, the peak antibody measured 1 hour after administration in the blood of participants was 11

338 times lower than the titer in the ConvP or COVIg unit but with a broad IQR of 5 to 20 times. This was 339 also observed by Shoham et al.(34) Although elimination half-life of pAbs is long, both the rapid 340 decline in titer and dose dilution are factors that should be taken into account during the practical 341 application of pAb-based prophylaxis in high-risk patients.

342 In this study, patients who were likely to or had been proven to lack an endogenous anti-SARS-CoV-2 343 antibody production as a result of B-cell depleting or B -and T-cell suppressive therapies were 344 recruited. In this way, the efficacy of ConvP and COVIg in this patient group could be investigated. 345 However, as the study had to be discontinued prematurely and only three patients had a 346 breakthrough infection during follow-up, no definite conclusions about the titers needed for protection 347 can be drawn. Furthermore, all 3 breakthrough infections occurred at a time when non-ancestral 348 variants were circulating to which the study products had reduced activity.

349 Since the start of the pandemic, many clinical studies on the efficacy of ConvP and to a lesser extend 350 also COVIg as a treatment for SARS-CoV-2 infected patients have been performed. The results of 351 these studies were mostly disappointing because in hospitalized non-immunocompromised patients 352 no clear beneficial effect was observed.(13, 16, 35-37) However, most of these trials were performed 353 with plasma from convalescent and non-vaccinated donors. Therefore, donors with extremely high 354 Nab-titers were rare. We previously summarized the available evidence on optimal dosing of ConvP 355 and concluded that patients were underdosed in almost all of these trials.(19) Furthermore, it has 356 become clear that antibody-based therapy works best when given in the first days after symptom 357 onset. Indeed, in a recent meta-analysis of the 6 double-blind randomized trials on ConvP performed 358 in outpatients with <8 days of symptoms, a significant reduction in hospital admission was only 359 observed when the intervention was given in the first 5 days of symptoms and when plasma with the 360 highest antibody titers was used.(17)

361 To explore the clinical application of the prophylactic use of ConvP and COVIg, a PTA was estimated 362 with a Monte Carlo simulation using 4 antibody titer targets ranging from 100 to 300 BAUmL $^{-1}$. These 363 titers were deemed relevant, as Feng et al. showed that a titer of 264 BAUmL $^{-1}$ was associated with 364 80% vaccine efficacy whereas Goldblatt et al. and Dimeglio et al. reported 150 BAUmL $^{-1}$ as sufficient 365 for offering protection.(38-40) However, protection against infection does not only come from humoral 366 immunity which may implicate that in patients with a B and T-cell deficiency higher titers may be

367 required. Also, subsequent variants of concern are often much more resilient to vaccine-induced 368 antibodies and higher titers are necessary to offer protection.(41) Dimeglio et al. showed that 369 achieving titers over 20.000 BAUmL⁻¹ are necessary to achieve at least 80% of protection against 370 Omicron infections.(42) In the current simulation, a PTA of 300 BAUmL $^{-1}$ was achieved by 371 administering ConvP or COVIg with at least 12,000 BAUmL⁻¹ every 4 weeks.

372 This study has its limitations. In SARS-CoV-2 uninfected patients, the final model can be used to 373 predict Nab-titers over time after an infusion of ConvP or COVIg. However, in patients infected with 374 COVID-19, exogenous antibodies probably have a shorter half-life due to the direct antibody-antigen 375 binding.(32) Also, with every new variant that occurs, the correlation of a SARS-CoV2 spike antibody 376 titer (in BAUmL⁻¹) with in vitro neutralization of this new variant should be evaluated again. This 377 means that for new variants, much higher targets (e.g. 10.000 rather than 300 BAUmL⁻¹) may be 378 necessary to result in any relevant protection. Fortunately, many plasma donors now have acquired 379 immunity from a combination of infection, vaccination and booster vaccination. Therefore, donors with 380 extremely high Nab-titers are readily identifiable. Unfortunately, due to the rapidly evolving variant 381 landscape of SARS-CoV-2 and the vaccination uptake, the study was discontinued prematurely and 382 only three breakthrough infections were detected. Therefore, a protective titer could not be estimated.

383 In conclusion, this is the first dose-finding study in which a population PK model describing Nab-titers 384 after ConvP and COVIg administration was constructed. Lean body weight and the type of pAbs 385 allowed to explain a part of the IIV for V1 and V2, respectively. This population PK model may be a 386 valuable tool for designing trials during future viral pandemics at the time when application of ConvP 387 or COVIg is considered as a prophylactic or therapeutic intervention.

389 **Study highlights (145/150 words)**

390

391 **What is the current knowledge on the topic?**

- 392 Although the pharmacokinetics of immunoglobulins have been elucidated, less is known about the
- 393 pharmacokinetics of target-specific polyclonal antibodies.
- 394

395 **What question did this study address?**

- 396 As the most optimal dosing regimens for convalescent plasma and hyperimmune globulins containing
- 397 anti-SARS-CoV-2 antibodies are unknown, a population pharmacokinetic analysis was performed.

398

399 **What does this study add to our knowledge?**

- 400 In this study, the population pharmacokinetic model of convalescent plasma and hyperimmune
- 401 globulins containing anti-SARS-CoV-2 antibodies is established for the first time. This way we were
- 402 able to show that very high-titer agents are needed to achieve an optimal dosing regimen for these
- 403 products.
- 404

405 **How might this change clinical pharmacology or translational science?**

- 406 The population PK model can be applied for designing trials during future pandemics if application of
- 407 polyclonal antibody therapy is considered as prevention against or treatment of viral infections.

409 **Acknowledgements**

- 410 We thank all volunteers that participated in the trial as well as all plasma donors.
- 411

412

413 **Author contributions**

- 414 BR, BK, SH, and TP designed the research. Research was performed by SH and supervised by BR.
- 415 SH and TP analyzed the data and TP constructed the population PK model. The manuscript was
- 416 written by SH and TP, the manuscript was reviewed by BR, BK, FS, IKB, and CG. BR did the overall
- 417 supervision of the project.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.03.07.23286893;](https://doi.org/10.1101/2023.03.07.23286893) this version posted March 9, 2023. The copyright holder for this preprint

References

1. Mathieu E. RH, Rodés-Guirao L., Appel C., Giattino C., Hasell J., Macdonald B., Dattani S., Beltekian D., Ortiz-Ospina E., Roser M. Coronavirus (COVID-19) Deaths: Our World in Data; 2022 [updated 30/11/2022; cited 2022 30/11/2022]. Available from: https://ourworldindata.org/covid-deaths. 2. Moreira ED, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. New England Journal of Medicine. 2022;386(20):1910-21. doi: 10.1056/NEJMoa2200674. PubMed PMID: 35320659. 3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020;383(27):2603-15. doi: 10.1056/NEJMoa2034577. PubMed PMID: 33301246. 4. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. Jama. 2021;326(20):2043-54. PubMed PMID: 34734975. 5. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. Jama. 2021;325(21):2204-6. doi: 10.1001/jama.2021.7489. 6. Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82(3):329-38. PubMed PMID: 33549624. 7. Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. New England Journal of Medicine. 2022;386(23):2188-200. doi: 10.1056/NEJMoa2116620. PubMed PMID: 35443106. 8. Herman GA, O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, et al. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2022;22(10):1444-54. PubMed PMID: 35803290. 9. Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, et al. Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies. bioRxiv. 2022:2022.05.03.490409. doi: 10.1101/2022.05.03.490409. 10. VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE, Purcell LA, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Medicine. 2022;28(3):490-5. doi: 10.1038/s41591-021-01678-y. 11. Focosi D, Tuccori M, Franchini M. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. Life (Basel). 2021;11(2). PubMed PMID: 33671893. 12. Alape-Girón A, Moreira-Soto A, Arguedas M, Brenes H, Buján W, Corrales-Aguilar E, et al. Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19. Frontiers in Medicine. 2021;8. doi: 10.3389/fmed.2021.743325. 13. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet. 2021;397(10289):2049-59. doi: https://doi.org/10.1016/S0140-6736(21)00897-7. 14. Huygens S, Hofsink Q, Nijhof IS, Goorhuis A, Kater AP, te Boekhorst PAW, et al. Hyperimmune globulin for severely immunocompromised patients hospitalized with COVID-19: a randomized, controlled trial. The Journal of Infectious Diseases. 2022. doi: 10.1093/infdis/jiac334. 15. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews. 2021(5). doi: 10.1002/14651858.CD013600.pub4. PubMed PMID: CD013600.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.03.07.23286893;](https://doi.org/10.1101/2023.03.07.23286893) this version posted March 9, 2023. The copyright holder for this preprint

16. Jorda A, Kussmann M, Kolenchery N, Siller-Matula JM, Zeitlinger M, Jilma B, et al. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis. Frontiers in Immunology. 2022;13. doi: 10.3389/fimmu.2022.817829. 17. Levine AC, Fukuta Y, Huaman MA, Ou J, Meisenberg BR, Patel B, et al. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials. Clinical Infectious Diseases. 2023. doi: 10.1093/cid/ciad088. 18. Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Network Open. 2023;6(1):e2250647-e. doi: 10.1001/jamanetworkopen.2022.50647. 19. Rijnders BJA, Huygens S, Mitjà O. Evidence-based dosing of convalescent plasma for COVID-19 in future trials. Clinical Microbiology and Infection. 2022;28(5):667-71. doi: https://doi.org/10.1016/j.cmi.2022.01.026. 20. Levine AC, Fukuta Y, Huaman MA, Ou J, Meisenberg BR, Patel B, et al. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials. medRxiv. 2022:2022.12.16.22283585. doi: 10.1101/2022.12.16.22283585. 21. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Eurosurveillance. 2021;26(27):2100568. doi: doi:https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100568. 22. Infantino M, Pieri M, Nuccetelli M, Grossi V, Lari B, Tomassetti F, et al. The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays. Int Immunopharmacol. 2021;100:108095. PubMed PMID: 34619529. 23. DiaSorin. Liaison SARS-CoV-2 TrimericS IgG assay: A quantitative assay for immune status monitoring with an accurate correlation of neutralizing IgG antibodies. Saluggia, Italy: 2021. 24. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347-8. PubMed PMID: 33770519. 25. Bauer RJ. NONMEM Tutorial Part I: Description of Commands and Options, with Simple Examples of Population Analysis. CPT Pharmacometrics Syst Pharmacol. 2019;8(8):525-37. PubMed PMID: 31056834. 26. Keizer RJ, Karlsson MO, Hooker A. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2(6):e50. PubMed PMID: 23836189. 27. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-57. PubMed PMID: 16023764. 28. Barahona Afonso AF, João CM. The Production Processes and Biological Effects of Intravenous Immunoglobulin. Biomolecules. 2016;6(1):15. PubMed PMID: 27005671. 29. Gordon O, Brosnan MK, Yoon S, Jung D, Littlefield K, Ganesan A, et al. Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. JCI Insight. 2022;7(2). PubMed PMID: 34855624. 30. Variants of the coronavirus SARS-CoV-2: National Institute for Public Health and the Environment; 2022 [updated 07/22/2022; cited 2022 07/25/2022]. Available from: https://www.rivm.nl/en/coronavirus-covid-19/virus/variants. 31. Kang TH, Jung ST. Boosting therapeutic potency of antibodies by taming Fc domain functions. Exp Mol Med. 2019;51(11):1-9. PubMed PMID: 31735912. 32. Stauft CB, Tegenge M, Khurana S, Lee Y, Selvaraj P, Golding H, et al. Pharmacokinetics and

Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of Severe Acute

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.03.07.23286893;](https://doi.org/10.1101/2023.03.07.23286893) this version posted March 9, 2023. The copyright holder for this preprint

Respiratory Syndrome Coronavirus 2 Infection in Adult Syrian Hamsters. Clinical Infectious Diseases. 2021;75(1):e459-e65. doi: 10.1093/cid/ciab854. 33. Marconato M, Abela IA, Hauser A, Schwarzmüller M, Katzensteiner R, Braun DL, et al. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. The Journal of Clinical Investigation. 2022;132(12). doi: 10.1172/jci158190. 34. Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, et al. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. Clinical Infectious Diseases. 2022. doi: 10.1093/cid/ciac372. 35. Polizzotto MN, Nordwall J, Babiker AG, Phillips A, Vock DM, Eriobu N, et al. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, 532 phase 3, randomised trial. The Lancet. 2022;399(10324):530-40. doi: https://doi.org/10.1016/S0140-6736(22)00101-5. 36. Libster R, Perez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021;384(7):610-8. Epub 2021/01/07. doi: 10.1056/NEJMoa2033700. PubMed PMID: 33406353; PubMed Central PMCID: 7793608. 37. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. New England Journal of Medicine. 2022;386(18):1700-11. doi: 10.1056/NEJMoa2119657. 38. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine. 2021;27(11):2032-40. doi: 10.1038/s41591-021-01540-1. 39. Dimeglio C, Herin F, Martin-Blondel G, Miedougé M, Izopet J. Antibody titers and protection against a SARS-CoV-2 infection. J Infect. 2022;84(2):248-88. PubMed PMID: 34560135. 40. Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunological Reviews. 2022;310(1):6-26. doi: https://doi.org/10.1111/imr.13091. 41. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. The Lancet Microbe. 2022;3(1):e52-e61. doi: 10.1016/s2666-5247(21)00267-6. 42. Dimeglio C, Migueres M, Bouzid N, Chapuy-Regaud S, Gernigon C, Da-Silva I, et al. Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection. Vaccines (Basel).

2022;10(9). PubMed PMID: 36146626.

557 **Figure legends**

- 558 **Figure 1. CONSORT flow diagram: patient enrollment and allocation of treatment.** For each of 559 the eight treatment cohorts (P1 to P4 and C1 to C4), the neutralizing antibody titers and the 560 administered volume are depicted. N depicts the number of patients assigned to the corresponding 561 treatment cohort.
- 562 Abbreviations: CLIA = chemiluminescent immuno-assay; ConvP = convalescent plasma; COVIg =
- 563 hyperimmune globulins containing anti-SARS-CoV-2 antibodies.
- 564

565 **Figure 2. Goodness-of-fit plot from the final model.**

566 (A) Population predicted versus measured neutralizing antibody levels as quantified using binding 567 antibody units per milliliter $(BAUmL^{-1})$. (B) Individual predicted versus measured neutralizing antibody 568 levels. (C) Conditional weighted residuals (CWRES) versus population predicted neutralizing antibody 569 levels. (D) CWRES versus time after dose administration. In Figure A and B, the blue line depicts the 570 locally weighted smoothing (LOESS) line, whereas in Figure C and D the red lines are the linear 571 regression line.

572

573 **Figure 3. Prediction-corrected Visual Predictive Check from the final model.**

574 A) pcVPC with the measured and simulated neutralizing antibody (Nab) titers on a linear scale (B)) 575 pcVPC with the observed and simulated neutralizing antibody (Nab) titers on a logarithmic scale. 576 Black dots represent the measured neutralizing antibody levels for all patients. Solid grey line 577 represents the median and the dashed grey lines represent the 2.5th and 97.5th quantiles for the 578 measured neutralizing antibody levels. Red and blue-shaded areas show the 95% confidence 579 intervals for the simulated neutralizing antibody titers of the individual patients, as obtained by 2000 580 Monte Carlo simulations using the final model.

581

582 **Figure 4. Probability of target attainment of simulated dosing regimens for ConvP and COVIg.**

583 For obtaining prediction for the neutralizing antibody levels, Monte Carlo simulations (n=2000) were 584 applied using the final model. Each row of figures depicts the probability of the target attainment 585 (PTA, %) for different target levels in BAUmL $^{-1}$ in the serum of the recipient, as displayed in the facet

- 586 header. The dashed line depicts 90% PTA, which was considered as the cut-off for having a
- 587 protective effect. The volume of ConvP was set at 600 mL and for COVIg of 300 mL.

- **Supplementary information titles**
- **Supplementary figure S1: Trial design**
- **Supplementary methods S2: Neutralizing antibody measurement**
- **Supplementary table S3: Baseline characteristics per subgroup**
- **Supplementary table S4. Terminal elimination half-life and AUC for ConvP and COVIg.**

Table 1. Demographics and baseline characteristics of the total patient population and treatment groups

Abbreviations: ConvP = convalescent plasma; COVIG = hyperimmune anti-SARS-Cov-2 globulins; CVID = common variable immune deficiency; HSCT = hematopoietic stem cell transplant; IQR = interquartile range; NK = natural killer; SOTx = solid organ transplant

^a Two mRNA vaccines, two vaccines by AstraZeneca or one Johnson & Johnson.
b Second vaccination (mRNA) in ages of vaccination with Johnson & Johnson.

Second vaccination (mRNA) in case of vaccination with Johnson & Johnson.

c District the U test was performed for continuous variables. Chi-square test was performed for categorical variables.

 $^{\text{d}}$ Fisher's exact test was performed since low amount of observations in at least one cell.

m,

Bootstrap analysis

RSE indicates relative standard error; Shr., shrinkage; CI, confidence interval as obtained using the 2.5th and 97.5th percentiles from the non-parametric distributions; CV, coefficient of variation; BAU, binding antibody units.

$$
CL_{i} (mLh^{-1}) = 9.1 x e^{\eta_{CL,i}}
$$

\n
$$
V1_{i} (mL) = 3790 x \left(\frac{LBW}{70}\right)^{0.538} x e^{\eta_{V1,i}}
$$

\n
$$
Q_{i} (mLh^{-1}) = 27.0
$$

\n
$$
V2_{i} (mL) = 1640 x 1.99^{cov/g} x e^{\eta_{V2,i}}
$$

in which the η_i represents the random effect for an individual patient associated to a PK parameter. The covariate value CONVP associated to the PK parameter V2 was 1 in the case ConvP and 0 in the case COVIg was administered. The bootstrap analysis was conducted using 2000 replicated datasets.

Table 3. Outcome per subgroup

IQR = interquartile range; SAEs = serious adverse events.

^a 36 patients were followed until antibodies were negative. P2: one missing – patient had a breakthrough infection, C4: one missing - patient had a breakthrough infection.

breakthrough infection.
^b Measured one hour after infusion.
^c C4: two missing due to logistical issues.